Omnicare's Specialty Care Group Advanced Care Scripts (ACS) to Provide Specialty Pharmacy Services for Novartis' Farydak®
March 05 2015 - 7:45AM
CINCINNATI, March 5, 2015 -
Advanced Care Scripts (ACS), a leading specialty pharmacy and
clinical services platform of Omnicare Specialty Care Group (SCG),
is proud to be part of the limited distribution network for the
Novartis drug Farydak® (panobinostat).
The US Food and Drug Administration (FDA) recently
approved Farydak® capsules in combination with bortezomib and
dexamethasone for the treatment of patients with multiple myeloma
who have received at least two prior regimens, including bortezomib
and an immunomodulatory (IMiD) agent.
Multiple myeloma is an incurable blood cancer, and
there is an urgent need for new treatments. Farydak is approved
under FDA's accelerated approval program; regulatory applications
are underway in the EU, Japan and worldwide. "We look forward to
providing our clinical services expertise in oncology to patients
prescribed this treatment option, and appreciate the opportunity to
be part of this limited distribution network," said Dennis Wilson,
VP & General Manager of Advanced Care Scripts.
Farydak has been shown to extend the
progression-free survival (PFS) benefit of the standard-of-care
therapy in this patient population. Farydak is approved under an
accelerated approval based on PFS. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in confirmatory trials. The FDA's accelerated
approval program gives patients access to treatments for serious or
life-threatening illnesses that provide meaningful therapeutic
benefit over existing treatments. The FDA has approved a risk
evaluation and mitigation strategy (REMS) for Farydak. The REMS
program serves to inform and educate healthcare professionals about
the risks that may be associated with Farydak treatment.
The goal of Advanced Care Scripts is to remove
barriers to access and increase speed to therapy. ACS has proven
experience in successfully managing and dispensing specialty
medications, such as Farydak, and related clinical services to
improve adherence to therapy and patient outcomes.
About Omnicare Specialty Care
Group
Omnicare Specialty Care Group (SCG) is a division of Omnicare,
Inc., a Fortune 500 company and provider of comprehensive
pharmaceutical services based in Cincinnati, Ohio. Omnicare SCG is
a combination of synergistic tenured companies with a focused
approach to pharmaceutical brand solutions. Together, Omnicare SCG
brings specialists in reimbursement methods, clinicians practiced
in medication therapy management for chronic disease states, and
distribution channel expertise. Solutions are tailored to drive
product access by solving challenges faced by patients and their
caregivers, physicians, payers and manufacturers. Custom programs
are led by a single management team across the organizational
platforms, allowing coordination of resources and assets to support
positive outcomes for our patients. For more information, visit
www.omnicarescg.com.
About Advanced Care
Scripts
Advanced Care Scripts, a specialty
pharmacy, manages and dispenses specialty medications and products
nationwide. It coordinates services beginning with the prescriber
to simplify reimbursement and delivery of biotech therapies used to
treat cancer, infectious diseases, auto-immune disorders, multiple
sclerosis, hemophilia, and other disease states. Its customer
service and comprehensive patient care model provides compliance
and adherence support and cost-effective solutions for all classes
of specialty medications.
# # #
Contact:
Patrick C. Lee
(513) 719-1507
patrick.lee@omnicare.com
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Omnicare via Globenewswire
HUG#1899546